Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA

Open source

DOI: 10.1136/jitc-2020-001511
Published: 2020 Dec
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2020-001511,
  title = {Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.},
  author = {Maus MV and Alexander S and Bishop MR and Brudno JN and Callahan C and Davila ML and Diamonte C and Dietrich J and Fitzgerald JC and Frigault MJ and Fry TJ and Holter-Chakrabarty JL and Komanduri KV and Lee DW and Locke FL and Maude SL and McCarthy PL and Mead E and Neelapu SS and Neilan TG and Santomasso BD and Shpall EJ and Teachey DT and Turtle CJ and Whitehead T and Grupp SA},
  year = {2020},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2020-001511},
  url = {https://doi.org/10.1136/jitc-2020-001511}
}

RIS

TY  - JOUR
TI  - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
AU  - Maus MV
AU  - Alexander S
AU  - Bishop MR
AU  - Brudno JN
AU  - Callahan C
AU  - Davila ML
AU  - Diamonte C
AU  - Dietrich J
AU  - Fitzgerald JC
AU  - Frigault MJ
AU  - Fry TJ
AU  - Holter-Chakrabarty JL
AU  - Komanduri KV
AU  - Lee DW
AU  - Locke FL
AU  - Maude SL
AU  - McCarthy PL
AU  - Mead E
AU  - Neelapu SS
AU  - Neilan TG
AU  - Santomasso BD
AU  - Shpall EJ
AU  - Teachey DT
AU  - Turtle CJ
AU  - Whitehead T
AU  - Grupp SA
PY  - 2020
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2020-001511
UR  - https://doi.org/10.1136/jitc-2020-001511
ER  -

APA

MV, M., S, A., MR, B., JN, B., C, C., ML, D., C, D., J, D., JC, F., MJ, F., TJ, F., JL, H., KV, K., DW, L., FL, L., SL, M., PL, M., E, M., SS, N., TG, N., BD, S., EJ, S., DT, T., CJ, T., T, W., & SA, G. (2020). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2020-001511

Source records

pubmed · retrieved 2026-09-26T23:53:17.097Z